The ATMC is a shared platform between the FMI and Novartis, established in 2024 alongside the FMI’s move to the Novartis campus. It brings together experts from both institutions to help researchers make use of advanced cellular models — including organoids — from initial optimization to fully automated, high-content screening.

Organoids are simplified, miniature organ models grown in the laboratory from patient-derived samples. In some cases, they serve as patient avatars, making them powerful models for both fundamental biological research and pharmaceutical development.

The facility spans around 200 m² of laboratory space (Biosafety Level 1 and 2), split between Fabrikstrasse 22 (Novartis) and Fabrikstrasse 24 (FMI).

Our support is structured as a three-step process in collaboration with the researchers:

• Model Development & Optimization
  We assist in building robust, reproducible, and biologically authentic model systems by integrating literature research, robotics, and media screening. This ensures that the cellular model faithfully reflects the biological question at hand.
• Miniaturization
  We down-scale models into multi-well plate formats and develop assays to ensure readiness for high-throughput or high-content screening.
• Perturbation & Screening
  We conduct fully automated large-scale screens, using modern chemical compound libraries or CRISPR knockout/interference/activation technologies, on optimized models to uncover biological insights.

Throughout every stage, researchers benefit from our combined expertise in complex model systems and advanced screening techniques. Many workflows are run on state-of-the-art automated platforms, including hypoxia-ready incubators, centrifuges, liquid handlers, washer-dispensers, and diverse readout systems such as confocal spinning disk microscopes, plate readers, and widefield imagers.

Contact
Maurice Kahnwald: Project leader ATMC